MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) today announces the launch of a new 600m² production wing at its Belgium site.
GOSSELIES, BELGIUM – MaSTherCell S.A. a subsidiary of Orgenesis Inc. (NASDAQ: ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO) today announces the launch of a new 600m² production wing at its Belgium site. The site has been launched today in the presence of the Public Health and Social Affairs Minister, Maggie De Block and the Minister-President of Wallonia, Willy Borsus. Masthercell is also backed by Great Point Partners, LLC (“GPP”), a leading healthcare investment firm based in Greenwich, Connecticut.
The expansion of the current Belgium plant will provide MaSTherCell five additional state-of-the-art late stage and commercial ready clean rooms. This new wing has been designed with an Agility–by-Design approach. This allows MaSTherCell’s clients adaptable clinical vs commercial segregation and clean room surface optimization for both isolation of certain parts of the facility and doubling of clean room size on demand.
“We are very pleased to announce the opening of our five new clean rooms exactly on schedule with the timeline we communicated to our partners. We are very proud of this facility expansion and we have also commenced planning for a commercial manufacturing facility. I sincerely want to thank the teams for their commitment and hard work in achieving these objectives,” said Eric Mathieu, Chief of Operations, MaSTherCell SA.
Each clean room of the new production wing is 30m² with an independent HVAC system to ensure full autonomy and independent maintenance management. The new wing also brings additional capabilities including two development laboratories, one quality control laboratory and additional warehouse capabilities.
“Providing MaSTherCell’s quality of service in late stage and commercial manufacturing was one of our priorities during the construction of the new infrastructure,” said Dr. Denis Bedoret, Managing Director of MaSTherCell SA. “The cell therapy industry and specifically our partners are eager to have access to reliable and additional state-of-the-art facilities for their commercial projection. Our objective is to help them access the market faster with tailor made capabilities. Today, we are pleased to offer these key assets to our partners and more widely to any cell therapy company facing a lack of production or development capacities.”
About MaSTherCell
MaSTherCell S.A. is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. MaSTherCell is a subsidiary of MaSTherCell Global Inc.– a gathering of MaSTherCell in Belgium, Atvio Biotech Ltd., an Israel-based CDMO, and Curecell Co. Ltd., a Korea-based CDMO partner. Masthercell Global is majority-owned by Orgenesis Inc. (Nasdaq:ORGS), a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 diabetes. At the heart of MaSTherCell is a team of highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. The company operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. For more information, please visit www.masthercell.com.
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital) and public (BioMedical Value Fund strategy, approximately $750 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.
.
